{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105487","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.769757+00:00","generated_at":"2026-05-17T16:50:24.327898+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR","bullets":["Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.","Cash $661.1M; runway into 1H'28; BLA submission for cretostimogene planned in Q4'25.","Jury unanimously ruled CG owes no future royalties to ANI, eliminating 5% commercial royalty.","BOND-003 Cohort C: 75.5% CR at any time; 12-mo CR 50.7%, 24-mo CR 42.3% (K-M); median DOR 28 mo.","CORE-008 Cohort CX (cretostimogene + gemcitabine) initiated in HR BCG-exposed NMIBC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105487","json":"https://secwatch.observer/filing/0000950170-25-105487.json","markdown":"https://secwatch.observer/filing/0000950170-25-105487.md","text":"https://secwatch.observer/filing/0000950170-25-105487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/0000950170-25-105487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/ck0001991792-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:50:24.327898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}